CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Lifestyle Modifications for Preventing and Treating Heart Failure INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors

Original Research2020 Jul 18.

JOURNAL:ESC Heart Fail. Article Link

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study

JA Borovac, D Glavas, ZS Grabovac et al. Keywords: acute decompensated heart failure; catestatin; HF; hospital mortality; risk stratification; soluble suppression of tumourigenicity

Full Text PDF